FDA approval

FDA approval

Colin Kerr

Published: Wednesday, May 1, 2019

Aerie Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Rocklatan™ to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. “Rocklatan is a once-daily eye drop that is a fixed-dose combination of latanoprost and netarsudil, the active ingredient in Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor specifically designed to target the trabecular meshwork. Rhopressa works by restoring outflow through the trabecular meshwork, while latanoprost increases fluid outflow through the uveoscleral pathway,” said a company spokesman. www.aeriepharma.com

Latest Articles

Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

New Award to Encourage Research into Sustainable Practices

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.

AI Scribing and Telephone Management

Automating note-taking and call centres could boost practice efficiency.

AI Analysis and the Cornea

A combination of better imaging and AI deep learning could significantly improve corneal imaging and diagnosis.

Cooking a Feast for the Eyes

A cookbook to promote ocular health through thoughtful and traditional cuisine.

Need to Know: Spherical Aberration

Part three of this series examines spherical aberration and its influence on higher-order aberrations.

Generating AI’s Potential

How generative AI impacts medicine, society, and the environment.